Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042938 · ClinicalTrials.gov registry record · Phase 2
Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01042938 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 35 participants.
The verdict
NCT01042938, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Ionizing radiation is a toxic agent and widely accepted form of treatment for various types of cancer. Despite advances in medical technology, radiation therapy still causes severe early and late skin effects. Radiation-induced dermatitis occurs in approximately 80% of patients. Important consequences of radiation-induced dermatitis include impairment of the quality of a patient's life due to pain and premature interruption of radiation treatment, which in turn, may be impair good local control of disease. The biological pathways responsible for acute radiation-induced dermatitis remain unclear. Currently, there is no standard treatment for the prevention of radiation-induced dermatitis with demonstrated effectiveness. The aim of this randomized, double-blind, placebo-controlled pilot study is to assess the effectiveness of curcumin for the prevention of acute radiation-induced dermatitis during postoperative radiotherapy for breast cancer. We hypothesize that curcumin, a natural phenolic compound found in both turmeric and curry powders, can prevent or alleviate radiation-induced skin reactions in breast cancer patients receiving radiotherapy.
Interventions
- DRUG Placebo
- DRUG Curcumin C3 Complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042938
The ClinicalTrials.gov registry entry for NCT01042938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042938 about?
NCT01042938 is a clinical study titled "Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients". Ionizing radiation is a toxic agent and widely accepted form of treatment for various types of cancer. Despite advances in medical technology, radiation therapy still causes severe early and late skin effects. Radiation-induced dermatitis occurs in approximately 80% of patients. Important consequenc...
What is the current status of trial NCT01042938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01042938?
The interventions under investigation include: Placebo (DRUG), Curcumin C3 Complex (DRUG).
Who is sponsoring clinical trial NCT01042938?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.